Invention Grant
- Patent Title: Pharmaceutical formulations containing an SGLT2 inhibitor
- Patent Title (中): 含有SGLT2抑制剂的药物制剂
-
Application No.: US14267984Application Date: 2014-05-02
-
Publication No.: US09198925B2Publication Date: 2015-12-01
- Inventor: Dilbir S. Bindra , Mandar V. Dali , Prakash V. Parab , Jatin M. Patel , Li Tao , Ravindra W. Tejwani , Nipa Vatsaraj , Yongmei Wu
- Applicant: AstraZeneca AB
- Applicant Address: SE Sodertalje
- Assignee: AstraZeneca AB
- Current Assignee: AstraZeneca AB
- Current Assignee Address: SE Sodertalje
- Agent Terence J. Bogie
- Main IPC: A61K31/7034
- IPC: A61K31/7034 ; A61K9/16 ; A61K31/403 ; A61K9/20 ; A61K45/06 ; A61K31/155 ; A61K31/70 ; A61K9/00 ; A61K9/08
Abstract:
Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
Public/Granted literature
- US20140243262A1 PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR Public/Granted day:2014-08-28
Information query
